Cost-Effectiveness of First-Line Regimens for Helicobacter pylori Infection in the United States

利福平 医学 幽门螺杆菌感染 内科学 幽门螺杆菌 螺杆菌感染 胃肠病学 螺旋藻科 免疫学 抗生素 抗生素治疗 药物治疗 抗菌剂
作者
Ligang Liu,Kang Wang,Marjorie V. Neidecker,Haoran Yang,Nahata C. Milap
出处
期刊:The American Journal of Gastroenterology [Lippincott Williams & Wilkins]
被引量:1
标识
DOI:10.14309/ajg.0000000000003924
摘要

INTRODUCTION: Helicobacter pylori infection remains a significant global health burden. The 2024 American College of Gastroenterology guideline recommended bismuth quadruple therapy (BQT) as the first-line treatment for treatment-naive patients. This study aimed to assess the cost-effectiveness of 5 regimens from a US healthcare payer perspective. METHODS: A Markov model was used to evaluate 5 H. pylori eradication regimens: (i) clarithromycin triple therapy, (ii) vonoprazan dual therapy, (iii) vonoprazan triple therapy, (iv) rifabutin triple therapy, and (v) BQT. We simulated a hypothetical cohort of treatment-naïve adults with H. pylori over 1-, 10-, 20-year and lifetime horizons. Model outcomes were measured in incremental cost-effectiveness ratios and net monetary benefit (NMB) at willingness-to-pay thresholds of $100,000 and $150,000/quality-adjusted life year. Deterministic and probabilistic sensitivity analysis was performed to assess model robustness. RESULTS: BQT had the lowest lifetime cost per patient ($193,651) and was used as the reference. Rifabutin and vonoprazan triple therapies had incremental cost-effectiveness ratios of $45,971 and $290,572 per quality-adjusted life year gained, respectively. Clarithromycin triple and vonoprazan dual therapies were dominated by BQT. Rifabutin triple therapy had the highest NMB, followed by BQT. Scenario analysis confirmed that rifabutin triple therapy maintained the highest NMB over 10- and 20-year horizons. Sensitivity analyses identified eradication rates of BQT were among the most influential parameters. Probabilistic sensitivity analysis showed rifabutin triple therapy had the highest probability of being cost-effective at both willingness-to-pay thresholds, followed by BQT. DISCUSSION: BQT was found to be the cost-effective first-line treatment. Rifabutin triple therapy was a cost-effective alternative. Policymakers should prioritize BQT and rifabutin triple therapy versus other therapies.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
细腻飞鸟发布了新的文献求助10
1秒前
Orange的应助被red采纳,获得10
1秒前
Brave发布了新的文献求助10
2秒前
往往发布了新的文献求助20
2秒前
小二郎的应助被入司采纳,获得10
2秒前
隐形曼青的应助被gshsj采纳,获得10
2秒前
何文鑫发布了新的文献求助10
2秒前
直率海莲发布了新的文献求助10
2秒前
如意白猫发布了新的文献求助10
3秒前
小蘑菇的应助被你好天空采纳,获得10
3秒前
共享精神的应助被你好天空采纳,获得10
3秒前
汉堡包的应助被你好天空采纳,获得10
3秒前
科研通AI6.3的应助被你好天空采纳,获得10
3秒前
JJKK的应助被你好天空采纳,获得10
3秒前
Akim的应助被你好天空采纳,获得10
3秒前
Lucas的应助被你好天空采纳,获得10
3秒前
Nole的应助被你好天空采纳,获得10
3秒前
华仔的应助被蟹老板的crab采纳,获得10
4秒前
领导范儿的应助被你好天空采纳,获得10
4秒前
852的应助被Daodao采纳,获得10
4秒前
JJKK的应助被你好天空采纳,获得10
4秒前
zj发布了新的文献求助10
4秒前
4秒前
XU完成签到,获得积分10
5秒前
5秒前
派大星完成签到,获得积分10
5秒前
6秒前
6秒前
瘦瘦寻菡完成签到,获得积分20
6秒前
Nole的应助被Jingxue_ZX采纳,获得30
7秒前
lbh发布了新的文献求助10
7秒前
放青松完成签到,获得积分10
9秒前
Hello的应助被细腻飞鸟采纳,获得10
9秒前
9秒前
晚风轻吹完成签到,获得积分10
9秒前
可爱的函函的应助被火山采纳,获得10
10秒前
精明之瑶完成签到,获得积分20
11秒前
可燃冰完成签到,获得积分10
11秒前
无限孤云完成签到,获得积分10
11秒前
yijiahu完成签到 ,获得积分10
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Agyptische Geschichte der 21.30. Dynastie 510
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8192250
求助须知:如何正确求助?哪些是违规求助? 9578881
关于积分的说明 21862513
捐赠科研通 7791814
什么是DOI,文献DOI怎么找? 3436868
关于科研通互助平台的介绍 2560584
邀请新用户注册赠送积分活动 2483698